Drug Combination Details
| General Information of the Combination (ID: C14052) | |||||
|---|---|---|---|---|---|
| Name | Delphinidin NP Info | + | TNF-related apoptosis inducing ligand Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Prostate cancer
[ICD-11: 2C82]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | TRAIL-R2 | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | LNCaP | CVCL_0395 | Prostate carcinoma | Homo sapiens | ||
| DU145 | CVCL_0105 | Prostate carcinoma | Homo sapiens | |||
| Experimental
Result(s) |
Delphinidin sensitizes prostate cancer cells to TRAIL-induced apoptosis, by inducing DR5 and causing caspase-mediated HDAC3 cleavage. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Delphinidin sensitizes prostate cancer cells to TRAIL-induced apoptosis, by inducing DR5 and causing caspase-mediated HDAC3 cleavage. Oncotarget. 2015 Apr 30;6(12):9970-84. | |||
